Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression |
| |
Authors: | CJ Smith AN Phillips B Dauer MA Johnson FC Lampe MS Youle M Tyrer S Staszewski |
| |
Affiliation: | Research Department of Infection and Population Health, Royal Free and University College Medical School, London, UK,;Department of Internal Medicine, JW Goethe University Hospital, Frankfurt, Germany and;Department of HIV Medicine, Royal Free Hospital, London, UK |
| |
Abstract: | Objective More and more highly treatment‐experienced patients are achieving viral suppression. However, the durability of suppression remains unclear. Methods Patients from Royal Free Hospital (London, UK) and JW Goethe University Hospital (Frankfurt, Germany) who had failed ≥1 antiretroviral (ARV) regimen in all three main drug classes and ≥3 previous ARV regimens and subsequently achieved viral load <50 HIV‐1 RNA copies/mL were included. They were followed until stopping pre‐combination antiretroviral therapy, end of follow‐up or viral rebound (two viral loads >400 copies/mL). Results Two hundred and forty‐seven patients contributed 723 person‐years and 114 viral rebounds [rate=15.8 per 100 person‐years; 95% confidence interval (CI) 12.9–18.7]. More recent calendar years of viral suppression [relative risk (RR)=0.90 per year later; 95% CI 0.81–1.00; P=0.05] and greater number of ARVs in the regimen not previously failed (RR=0.78 per 1 ARV more; 95% CI 0.65–0.95; P=0.01) were associated with lower viral rebound rates. At 0–1, 1–2, 2–3 and >3 years after achieving suppression, the rebound rates were 30.9, 9.2, 4.3 and 3.5 per 100 person‐years, respectively. Compared to 0–1 years, the adjusted RRs (95% CIs) after 1–2, 2–3 and >3 years were 0.33 (0.18–0.58), 0.21 (0.09–0.48) and 0.14 (0.06–0.33), respectively (P<0.0001). Conclusions Although rebound rates are high, especially in the first year after viral suppression, this risk reduces substantially if highly treatment‐experienced patients can maintain viral suppression. |
| |
Keywords: | antiretroviral therapy three-class failure viral rebound |
|
|